MALVERN, Pa.--(BUSINESS WIRE)--Encore Dermatology, Inc. announced today that it has begun to commercialize Hylatopic®, Tetrix™, and BenzEFoam™, three highly regarded and established U.S. topical dermatology products acquired from Valeant Pharmaceuticals North America, LLC and certain of its affiliates.
Encore Dermatology, Inc. is a privately held company headquartered in Malvern, Pennsylvania. Encore Dermatology is committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients. Encore brings together the former leadership team of Precision Dermatology which was sold to Valeant in 2014. William Crouse is Chairman; Bob Moccia - President and CEO; Rick Havens - Executive Vice President, Sales and Marketing; Boris Meyerson, Ph.D. - Executive Vice President, Business Operations; Kent Taylor - Vice President, Marketing; and Tim Waite - Vice President, Sales. Additionally, Charles W. Stiefel, the former Chairman and CEO of Stiefel Laboratories, has agreed to join the board of directors of Encore. Bob Moccia states: “We are very excited about this new opportunity to launch a company which understands what dermatologists have always told us; they want effective and safe products and services from companies and people they know and trust.” Encore will have a wide range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis. Encore Dermatology is rapidly expanding through acquisitions, in-licensing, and co-marketing opportunities.
About Encore Dermatology, Inc.
Headquartered in Malvern, Pennsylvania, Encore Dermatology is a privately held fully-integrated specialty dermatology company with a mission committed to delivering innovative prescription therapies and medical devices to dermatologists focusing on customer service and improving the quality-of-life of patients. In addition to the founders, principal investors will be Essex Woodlands, 1315 Capital and Longitude Capital. For additional information, please visit www.encorederm.com.